Added to YB: 2025-10-22
Pitch date: 2025-10-20
SOBI.ST [neutral]
Swedish Orphan Biovitrum AB (publ)
+7.43%
current return
Author Info
Nordic Edge provides actionable insights and alpha-generating opportunities in the Nordics. Sign up for the newsletter.
Company Info
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
Market Cap
N/A
Pitch Price
SEK 306.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
N/A
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Swedish Orphan Biovitrum (SOBI) Q3-2025 Earnings Review
SOBI.ST (earnings): Q3 rev SEK 7,776m (+13% y/y, +21% CC) beat on Altuvoct/Doptelet strength; FY25 guidance raised to LDD growth & mid-to-high 30s EBITA margin. Vonjo disappointment led to SEK 6.6bn impairment. Beyfortus royalty weak on slow RSV season. Strong FCF generation continues.
Read full article (2 min)